Edgewise Therapeutics Inc (EWTX)
$18.98
+0.25
(+1.33%)▲
Market is closed - opens 7 PM, 29 Jul 2024
Performance
- $18.73$20.21$18.98
1.32%
Downside
Day's Volatility :7.32%
Upside
6.09%
- $5.12$23.50$18.98
73.02%
Downside
52 Weeks Volatility :78.21%
Upside
19.23%
Returns
| Period | Edgewise Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 15.83% | 6.5% | 0.0% |
6 Months | 13.38% | 7.1% | 0.0% |
1 Year | 159.06% | 9.8% | 0.0% |
3 Years | -7.23% | 14.2% | -20.2% |
Highlights
Market Capitalization | 2.0B |
Book Value | $5.74 |
Earnings Per Share (EPS) | -1.54 |
Wall Street Target Price | 33.6 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -17.14% |
Return On Equity TTM | -24.51% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -121.6M |
Diluted Eps TTM | -1.54 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.58 |
EPS Estimate Next Year | -1.98 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.38 |
Analyst Recommendation
Buy
91%Buy
8%Hold
0
0%Sell
Based on 12 Wall street analysts offering stock ratings for Edgewise Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
- Current
- 1M Ago
- 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 77.03%
Current $18.98
Target $33.60
Technicals Summary
Sell
Neutral
Buy
Edgewise Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Edgewise Therapeutics Inc | 7.15% | 13.38% | 159.06% | -7.23% | -34.46% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Edgewise Therapeutics Inc | 3.7 | NA | NA | -1.58 | -0.25 | -0.17 | NA | 5.74 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Edgewise Therapeutics Inc | Buy | $2.0B | -34.46% | 3.7 | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Edgewise Therapeutics Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 193.7%
Institutional Holdings
Orbimed Advisors, LLC
16.08%RA Capital Management, LLC
9.54%FMR Inc
6.81%Baker Bros Advisors LP
6.25%BlackRock Inc
5.53%Vanguard Group Inc
4.30%
Company Information
edgewise therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle. the company is headquartered in boulder, co and received its series a financing from orbimed.
Organization | Edgewise Therapeutics Inc |
Employees | 92 |
CEO | Dr. Peter A. Thompson FACP, M.D. |
Industry | Healthcare |
